ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0558 • ACR Convergence 2024

    Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data

    Maureen Dubreuil1, Marina Magrey2, Kathrin Haeffs3, Evgueni Ivanov4 and Julie Gandrup Horan5, 1Section of Rheumatology, Boston University School of Medicine, Boston, MA, 2Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Bulle, Switzerland, 5UCB Pharma, Slough, United Kingdom

    Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
  • Abstract Number: 0482 • ACR Convergence 2024

    Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis

    Vanshika Sabharwal1 and Ashit Syngle2, 1MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India, 2Healing Touch City Clinic, Chandigarh, Chandigarh, India

    Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…
  • Abstract Number: 0388 • ACR Convergence 2024

    The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

    Samantha Morin1, KAREN BEATTIE2, Roxana Bolaria3, Tania Cellucci4, Gaelle Chedeville5, Amieleena Chhabra6, Paul Dancey7, Tommy Gerschman8, Liane Heale9, Julie Herrington2, Adam Huber10, Mehul Jariwala11, Jean-Philippe Proulx-Gauthier12, Dax Rumsey13, Heinrike Schmeling14, Jaime Guzman15 and Michelle Batthish4, and CAPRI Registry Investigators, 1McMaster University, Hamilton, Canada, 2McMaster University, Hamilton, ON, Canada, 3Victoria Arthritis Center, Victoria, BC, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada, 5The Montreal Children's Hospital, Montreal, QC, Canada, 6University of British Columbia, Penticton, BC, Canada, 7Memorial University, St. John's, Canada, 8University of British Columbia - Vancouver, North Vancouver, BC, Canada, 9McMaster University, Oakville, ON, Canada, 10IWK Health Centre, Halifax, NS, Canada, 11Jim Pattison Children's Hospital, Saskatoon, Canada, 12CHU de Quebec - Universite Laval, Quebec, QC, Canada, 13University of Alberta, Edmonton, AB, Canada, 14University of Calgary, Calgary, AB, Canada, 15University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
  • Abstract Number: 0563 • ACR Convergence 2024

    Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort

    Manouk de hOoge1, Pedro M. Machado2, Sytske Anne Bergstra3, Maxime Dougados4, Clementina López Medina5, Victoria Navarro Compán6, Diego Benavent7, Denis Poddubnyy8, Levent kilic9, Philippe Carron10, Dirk Elewaut11, Filip Van den Bosch12 and Gaelle Varkas12, 1Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3LUMC, Leiden, Netherlands, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Reina Sofia University Hospital, Cordoba, Spain, 6La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 7Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 8Charite-Universitatsmedizin Berlin, Berlin, Germany, 9Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 10UZ Gent, Gent, Belgium, 11Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 12Ghent University Hospital, Ghent, Belgium

    Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
  • Abstract Number: 0573 • ACR Convergence 2024

    Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data

    Ansaam Daoud1, Jennifer Murphy2, Omer Pamuk3 and Marina Magrey4, 1Case Western Reserve University/University Hospitals, Akron, OH, 2University Hospitals, Cleveland, OH, 3University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 4Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH

    Background/Purpose: A large proportion of patients with ankylosing spondylitis (AS) are considered difficult to treat (D2T).The study aimed to compare baseline characteristics, extra-articular manifestations (EAM),…
  • Abstract Number: 0580 • ACR Convergence 2024

    Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis

    Ayantika Talukdar1, Neke Ibeh2, Rohan Machhar2, Mansi Aparnathi3, Sareh Keshavarazi4, Archita Srinath5, Akihiro Nakamura6, Robert Inman7, Proton Rahman8, Igor Jurisica9 and Nigil Haroon10, 1Krembil Research Institute, UHN, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3University Health Network, Toronto, Canada, 4UHN, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Queen's Univesity, Kingston, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 9Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 10Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
  • Abstract Number: 0570 • ACR Convergence 2024

    Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients

    Halah Alfatlawi1, abdulmajeed alharbi2, eun seo kwak2, rawnag el sheikh2 and nezam altorok2, 1the university of toledo, Toledo, OH, 2the university of toledo, Toledo

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
  • Abstract Number: 0544 • ACR Convergence 2024

    A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort

    Ana Bento da Silva1, Sofia Ramiro2, Miranda van Lunteren1, Mary Lucy Marques3, Marleen Van De Sande4, Camilla Fongen5, Sofia Exarchou6, Roberta Ramonda7, Desiree van der Heijde8 and Floris van Gaalen9, 1Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center, Bunde, Netherlands, 3Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, 4Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, 5Diakonhjemmet Hospital, Oslo, Norway, 6Lund University, Åkarp, Sweden, 7Rheumatology Unit, University of Padova, Italy, Padova, Italy, 8Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 9LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: Axial spondyloarthritis (axSpA) frequently leads to reduced spinal and hip mobility, though evidence pertains mostly to patients with longstanding disease and radiographic damage. More…
  • Abstract Number: 0572 • ACR Convergence 2024

    Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

    Patricia Remalante-Rayco1, Emmanuel Baja2, Zeynep Baskurt3, Tina Chim4, Robert Inman5, Leonila Dans6 and Nigil Haroon7, 1Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, 3Department of Biostatistics, University Health Network, Toronto, Canada, 4Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 5University Health Network, Toronto, ON, Canada, 6Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
  • Abstract Number: 0556 • ACR Convergence 2024

    Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis

    Asier García-Alija1, Hye Sang Park1, Patricia Moya1, Ana Laiz1, Carla Marco2, Albert Casals1, Concepcion Pitarch2, Cesar Diaz-Torné1, Berta Paula Magallares3, Ivan Castellvi Barranco1, Susana Fernández-Sánchez1, Andrea García-Guillen2, Jose Luis Tandaipan1, Helena Codes-Mendez1, Guillem Verdaguer1, Luis Sainz1 and Hèctor Corominas1, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital Dos de Maig, Barcelona, Spain, 3Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain

    Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…
  • Abstract Number: 0543 • ACR Convergence 2024

    Impact of Peripheral Manifestations on Function, Health, and Work Productivity in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study

    Clementina López Medina1, Anna Molto2, Dafne Capelusnik3 and Sofia Ramiro4, 1Reina Sofia University Hospital, Cordoba, Spain, 2Groupe Hospitalier Cochin, AP-HP, Paris, France, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Peripheral musculoskeletal manifestations can occur either concomitantly with axial disease or independently in patients with spondyloarthritis (SpA). However, it is not known whether the…
  • Abstract Number: 0473 • ACR Convergence 2024

    Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology

    NATALUCCI Francesco1, SOKOLOVA Tatiana2, NZEUSSEU TOUKAP Adrien3, GALANT Christine4, ABOUBAKAR Frank5, BAURAIN Jean-François6, CORNELIS Frank6, BORBATH Yvan7, DUREZ Patrick2 and MERIC de BELLEFON Laurent2, 1Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 4Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 5Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, 6Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 7Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium

    Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…
  • Abstract Number: 0552 • ACR Convergence 2024

    Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study

    Andre Ramon1, Philippe Saas2, Charline Vauchy3, Maxime Samson2 and ERIC TOUSSIROT4, 1Dijon University Hospital, Besançon, France, 2Franche-Comté University, EFS, INSERM, UMR RIGHT, Besançon, France, Besançon, France, 3INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, 4university hospital of BESANCON, besancon, France

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate immune T cells that are located at the mucosal barriers. They play a role in mucosal defense,…
  • Abstract Number: 0583 • ACR Convergence 2024

    Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

    Alexis Ogdie1, Philip Mease2, Francois Nantel3, Frederic Lavie4, Mohamed Sharaf5, Emmanouil Rampakakis6, Helena Marzo-Ortega7 and Laure Gossec8, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 3Nantel MedSci Consult, Montreal, QC, Canada, 4Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 5Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 8Sorbonne Université, Paris, France

    Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
  • Abstract Number: 0525 • ACR Convergence 2024

    Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

    Varun Dhir1, Harshith Sai Koneti2, Aman Sharma3, sanjay jain4 and shankar naidu5, 1PGIMER, CHD, INDIA, CHANDIGARH, India, 2PGIMER, Chandigarh, Sangareddy, Telangana, India, 3PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 4PGIMER, Chandigarh, Chandigarh, India, 5PGIMER, Chandigarh, India, Chandigarh, India

    Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
  • « Previous Page
  • 1
  • …
  • 265
  • 266
  • 267
  • 268
  • 269
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology